memantine / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 111 Diseases   73 Trials   73 Trials   1509 News 


«12...1314151617181920212223...3637»
  • ||||||||||  memantine / Generic mfg.
    Clinical, Review, Journal, Real-world evidence:  Dual-acting agents for improving cognition and real-world function in Alzheimer's disease: Focus on 5-HT6 and D3 receptors as hubs. (Pubmed Central) -  Aug 14, 2021   
    To date, there are no interventions that impede the inexorable progression of Alzheimer's disease (AD), and currently-available drugs cholinesterase (AChE) inhibitors and the N-Methyl-d-Aspartate receptor antagonist, memantine, offer only modest symptomatic benefit...Finally D3 antagonism may counter psychotic episodes and D3 receptors themselves offer a promising hub for multi-target agents. The present article reviews the status of "R and D" into multi-target 5-HT6 and D3 ligands for improved treatment of AD and other neurodegenerative disorders of aging.
  • ||||||||||  memantine / Generic mfg.
    Predicting interactions of Aβ and the NMDA receptor using molecular docking and simulations (Room: B313b - B314) -  Aug 13, 2021 - Abstract #ACSFall2021ACS_Fall_8176;    
    Several treatments for AD focus on regulating the activity of NMDAR through inhibition, e.g., memantine...We find that a single amino acid substitution with known changes to developing AD results in distinct interaction profiles in our rigid body docking experiments. We also find overlaps between active molecule binding locations and predicted docking models with all Aβ isoforms.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Potential therapeutic natural products against Alzheimer's disease with Reference of Acetylcholinesterase. (Pubmed Central) -  Aug 13, 2021   
    In this review we summarize the studies reporting phytocompounds and extracts from medicinal plants that show AChE inhibitory activities and could be of potential benefit in AD. Future research directions are suggested and recommendations made to expand the use of medicinal plants and their formulations to prevent, mitigate and treat AD.
  • ||||||||||  memantine / Generic mfg.
    [VIRTUAL] MANAGEMENT OF NEUROPSYCHIATRIC SYMPTOMS IN DEMENTIA (Topic B) -  Aug 6, 2021 - Abstract #WCN2021WCN_561;    
    In this presentation, both pharmacological and non-pharmalogical management of the most common neuropsychiatric symptoms in Alzheimer’s disease, frontotemporal dementia, Lewy body dementia, and vascular dementia will be reviewed. We will also discuss the place of cholinesterase inhibitors and memantine in the treatment of neuropsychiatric symptoms in dementia.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    Review, Journal:  Multi-Target Drug Candidates for Multifactorial Alzheimer's Disease: AChE and NMDAR as Molecular Targets. (Pubmed Central) -  Aug 6, 2021   
    On the other hand, memantine is the only non-competitive NMDAR antagonist approved in AD treatment...This review focus on the significance of privileged scaffolds in the generation of the multi-target lead compound for treating AD, investigating the idea and challenges of multi-target drug design. Furthermore, the most auspicious elementary units for designing as well as synthesizing hybrid drugs are demonstrated as pharmacological probes in the rational design of new potential AD therapeutics.
  • ||||||||||  memantine / Generic mfg.
    Magnetoencephalography insights to dementia and drug intervention. (Convention Ctr - Four Seasons Ballroom 4) -  Aug 2, 2021 - Abstract #AAIC2021AAIC_2512;    
    It is sensitive to disease and individual differences in pathophysiology, reliable, safe, well-tolerated and sufficiently scalable for early phase trials. MEG evidence of selective neuronal dysfunction and network reorganisation can couple with microcircuit models for synaptic assays, or be used directly as a readout for interventional studies.
  • ||||||||||  memantine / Generic mfg.
    [VIRTUAL] Quantitative systems pharmacology model of the effect of tau hyperphosphorylation on synaptic plasticity () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_2421;    
    Various data on synaptic plasticity in presence of different effectors (amyloid beta, memantine, SSR180711 etc.), available from the literature, are used for verification...It demonstrates that: 1) tau with anti-aggregant properties may lead to a robust LTP, that was even more pronounced than control tau 2) antibody to tau decreases tau hyperhyperphosphorylation and restores LTP reduced by OA influence 3) inhibition of GSK-3b kinase leads attenuates hyperphosphorylation and leads to recovery of LTP Conclusion : The QSP model describes an influence of tau hyperphosphorylation on receptor’s excitotoxicity and released calcium from ER (high activity of PP2b, increased intracellular calcium concentration). Our model allows to explore change of LTP under the influence of tau targeting therapy.
  • ||||||||||  Kinaction (masitinib) / AB Science
    Masitinib in mild to moderate Alzheimer’s disease: Results from study AB09004 (Convention Ctr - Four Seasons Ballroom 1) -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1821;    
    Eligible patients that had a clinical diagnosis of AD with baseline mini-mental state examination (MMSE) score ≥12–≤25, and had received a stable dose of cholinesterase inhibitor (donepezil, rivastigmine or galantamine) and/or memantine for ≥6 months, were treated for 24 weeks. Masitinib (4.5mg/kg/day), a tyrosine kinase inhibitor targeting mast cell and microglia activity, may provide a new treatment option for mild to moderate AD.
  • ||||||||||  memantine / Generic mfg.
    [VIRTUAL] Clinical characteristics and treatments in patients with chronic kidney disease and dementia. () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1755;    
    Patients with advanced chronic kidney disease had worse cognitive function and less prescribed anti-dementia drugs. Since we have previously shown that aChEI treatment is associated with lower mortality, the relationship between anti-dementia medication, renal function and cognition must be further investigated.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Populacional epidemiological study of dementia in the city of Londrina - Paraná - Brazil () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1441;    
    Rates of AD medication non-adherence and discontinuation were substantial and may relate to cost and access to care. It has been concluded that additional studies are needed to prove the potential risk factors for dementias, so that an early approach and prevention of this disease can be invested in, improving care even more.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Dementia care in diverse older adults in the Deep South and the rest of the US () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_1094;    
    ADRD specialist and drug utilization is relatively low in both DS and non-DS, with no significant R/E differences. Research should continue to examine factors that may drive medical care decisions of older adults with ADRD in US regions with different socio-economic and medical resource contexts.
  • ||||||||||  donepezil / Generic mfg., galantamine hydrobromide / Generic mfg., memantine / Generic mfg.
    [VIRTUAL] Care Processes Related to Clinical Detection of Alzheimer’s Disease in the US Veterans Affairs Healthcare System () -  Aug 2, 2021 - Abstract #AAIC2021AAIC_947;    
    Prior to the first ICD coding, 53.1% received codes for non-specific dementia and 29.4% for mild cognitive impairment (MCI), with the first code appearing an average of 3 years before the first AD code. In the year before the first AD code, 51.1% visited specialists, 25.7% received neuropsychological assessments, 31.3% had brain imaging (but only 1.3% had a fluorodeoxyglucose-PET scan), 30.2% received prescriptions for dementia medication, 45.8% received community-based services, and 15.0% were admitted to institutional long-term care.
  • ||||||||||  memantine / Generic mfg.
    Journal:  Novel NMDA-receptor antagonists ameliorate vanadium neurotoxicity. (Pubmed Central) -  Jul 30, 2021   
    Various NMDA-receptor antagonists have been investigated for their therapeutic potential in Alzheimer's disease with memantine shown to be safe and with relative efficacy...In addition, the observed degeneration included demyelination, increased GFAP-immunoreactive cells and microgliosis. Simultaneous administration of the compounds to vanadium-exposed mice resulted in the preservation of cellular integrity in the same anatomical regions and restoration of the cells' vitality with reduced astroglial and microglial activation.
  • ||||||||||  memantine / Generic mfg.
    Clinical, Journal:  Circadian changes in Alzheimer's disease: Neurobiology, clinical problems, and therapeutic opportunities. (Pubmed Central) -  Jul 30, 2021   
    Following recent epidemiological data showing associations of AD incidence with modern societal and "life-style"-related risk factors, also nonpharmacological interventions, including sleep optimization, are being developed and some have been shown to be beneficial. Circadian aspects in AD are relevant from a pathophysiological standpoint, but they can also have an important role in pharmacologic and nonpharmacologic interventions, and appropriate timing of sleep, meals, and medication may boost therapeutic efficacy.
  • ||||||||||  memantine / Generic mfg., carbamazepine / Generic mfg.
    PK/PD data, Preclinical, Journal:  Pharmacokinetic and tissue distribution study of ZCY-15, a novel compound against Alzheimer's disease, in rats byliquid chromatography-tandem mass spectrometry. (Pubmed Central) -  Jul 16, 2021   
    ZCY-15, N-(3,5-dimethyladamatan-1-yl)-N-(3-methylphenyl) urea, is a candidate compound synthesized from the memantine structure and has been shown to be remarkably effective in treating Alzheimer's disease...According to the dissolution characteristics, the plasma samples were prepared by acetonitrile protein precipitation and carbamazepine was selected as the internal standard (IS)...It has been shown that ZCY-15 could pass through the blood-brain barrier and was highly concentrated in the hippocampus. We established the first bioanalytical method to quantify ZCY-15 in rodent bio-samples for ongoing pharmacokinetic and tissue distribution studies, and the results were expected to lay foundation for the subsequent studies.
  • ||||||||||  ketamine / Generic mfg., memantine / Generic mfg.
    Preclinical, Journal:  Molecular mechanisms for the antidepressant-like effects of a low-dose ketamine treatment in a DFP-based rat model for Gulf War Illness. (Pubmed Central) -  Jul 15, 2021   
    Interestingly, treatment with ANA-12, a TrkB-BDNF receptor antagonist, in DFP rats blunted ketamine's antidepressant-like effect at 24-h but not at 1-h. These experiments suggest that in a rat model of DFP-induced depression, inhibition of the NMDAR-Ca contributes to the rapid-onset antidepressant effects of ketamine while the antidepressant actions that persisted at 24-h post ketamine administration involve upregulation of BDNF signaling.
  • ||||||||||  memantine / Generic mfg.
    Clinical, Journal:  Genesis of Quality Measurements to Improve the Care Delivered to Patients With Brain Metastases. (Pubmed Central) -  Jul 14, 2021   
    Other performance measurements included 30-day postoperative readmission rate (6%), SRS within 30 days of surgery (79%), use of memantine with WBRT (41%), advance directives within 6 months of diagnosis (53%), and palliative care consultation for patients with poor prognosis or receiving WBRT (45%)...We propose a set of measurements to apprise quality improvement efforts, inform treatment decision-making, and to use in evaluation of the performance of interdisciplinary BMs programs. Their refinement can potentially enhance the quality and value of care delivered to patients with BMs.